Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei
暂无分享,去创建一个
[1] A. Guerrero,et al. Selection ofCandida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis , 1997, European Journal of Clinical Microbiology and Infectious Diseases.
[2] M. Bard,et al. Candida albicans Sterol C-14 Reductase, Encoded by the ERG24 Gene, as a Potential Antifungal Target Site , 2002, Antimicrobial Agents and Chemotherapy.
[3] C. Munro,et al. Anti-fungal therapy at the HAART of viral therapy. , 2002, Trends in microbiology.
[4] J. Maguire,et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. , 2002, The New England journal of medicine.
[5] Joseph Heitman,et al. Calcineurin is essential for survival during membrane stress in Candida albicans , 2002, The EMBO journal.
[6] P. Nghiem,et al. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. , 2002, Journal of the American Academy of Dermatology.
[7] J. Heitman,et al. Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR , 2001, Antimicrobial Agents and Chemotherapy.
[8] D. Simon,et al. Infectious complications of solid organ transplantations. , 2001, Infectious disease clinics of North America.
[9] Nina Singh,et al. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. , 2001, Emerging infectious diseases.
[10] D. Poutsiaka. Antimicrobial resistance in the chronically critically ill patient. , 2001, Clinics in chest medicine.
[11] M. Libman,et al. Prevalence and Antifungal Susceptibility of 442Candida Isolates from Blood and Other Normally Sterile Sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, Canada , 2001, Journal of Clinical Microbiology.
[12] D. Sanglard,et al. Fluconazole plus Cyclosporine: a Fungicidal Combination Effective against Experimental Endocarditis Due to Candida albicans , 2000, Antimicrobial Agents and Chemotherapy.
[13] R. Auten,et al. When to Suspect Fungal Infection in Neonates: A Clinical Comparison of Candida albicans and Candida parapsilosis Fungemia With Coagulase-Negative Staphylococcal Bacteremia , 2000, Pediatrics.
[14] D. Sanglard,et al. Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans , 2000, Antimicrobial Agents and Chemotherapy.
[15] R. Hay. The management of superficial candidiasis. , 1999, Journal of the American Academy of Dermatology.
[16] S. Kohno,et al. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. , 1998, The Journal of antimicrobial chemotherapy.
[17] F. T. P. Group,et al. International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program , 1998, Journal of Clinical Microbiology.
[18] M. Bard,et al. Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants , 1998, Antimicrobial Agents and Chemotherapy.
[19] T. C. White,et al. Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.
[20] Ronald N. Jones,et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. , 1998, Diagnostic microbiology and infectious disease.
[21] S. Kohno,et al. Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains , 1998 .
[22] J. Heitman,et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein , 1997, Antimicrobial agents and chemotherapy.
[23] S. Kelly,et al. Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[24] S. Kelly,et al. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance , 1996, Antimicrobial agents and chemotherapy.
[25] A. Sierra,et al. Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. , 1996, Chemotherapy.
[26] D. Snydman,et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.
[27] Anna Tempczyk,et al. Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complex , 1995, Nature.
[28] P. Caron,et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex , 1995, Cell.
[29] M. Su,et al. Interaction of FKBP12-FK506 with Calcineurin A at the B Subunit-binding Domain (*) , 1995, The Journal of Biological Chemistry.
[30] R. S. Muir,et al. Targets of immunophilin‐immunosuppressant complexes are distinct highly conserved regions of calcineurin A. , 1995, The EMBO journal.
[31] J. Rex,et al. Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.
[32] F. McKeon,et al. The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation , 1994, Cell.
[33] J. Springer,et al. FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. , 1994, The Journal of biological chemistry.
[34] R. Handschumacher,et al. Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. , 1993, The Journal of biological chemistry.
[35] D. Irwin,et al. Isogenic strain construction and gene mapping in Candida albicans. , 1993, Genetics.
[36] C. Beck-Sague,et al. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.
[37] J J Burbaum,et al. Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. , 1993, The Journal of biological chemistry.
[38] M G Rinaldi,et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. , 1991, The New England journal of medicine.
[39] A. Jandrositz,et al. The gene encoding squalene epoxidase from Saccharomyces cerevisiae: cloning and characterization. , 1991, Gene.
[40] F. Karst,et al. In vivo effects of fenpropimorph on the yeast Saccharomyces cerevisiae and determination of the molecular basis of the antifungal property , 1990, Antimicrobial Agents and Chemotherapy.
[41] P. Marichal,et al. Anti-Candida drugs--the biochemical basis for their activity. , 1987, Critical reviews in microbiology.
[42] H. Vanden Bossche. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. , 1985, Current topics in medical mycology.
[43] F. Odds,et al. Candida and candidosis , 1979 .
[44] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .